Browse drugs

…act of Vein-to-vein Time in Patients With R/R LBCL Treated with Axicabtagene Ciloleucel. Blood Adv. 2025 Jun 10;9(11):2663–2676. doi: 10.1182/bloodadva…

…in over one-third of patients, especially in DLBCL treated with axicabtagene ciloleucel, while none were reported with tisagenlecleucel. Despite low mo…

…y with axicabtagene ciloleucel (axi-cel). Bridging therapy with polatuzumab plus rituximab, followed by Axi-cel infusion after a standard l…

…l (axi-cel), 31 (42%) tisagenlecleucel (tisa-cel), and 11 (16%) brexucabtagene autoleucel (brexi-cel). Mean V2Vt was 48±19 days (median 42) for axi-cel, …

…mplications.Conclusion and Relevance In this real-world cohort, axi-cel showed predictable but significant toxicity, including universa…

…, 1 (64.9%; 24p). Seven had prior transplants: five autologous. Axi-cel was: 78.4% third-line; 18.9% fourth-line, 2.7% sixth-line. Medi…

…32%). In FL, CAR-T products such as axicabtagene ciloleucel and lisocabtagene maraleucel achieve CR rates up to 94%, with median durations of remission …

…e-treatment tumor biopsies from r/r DLBCL patients treated with axicabtagene ciloleucel (axi-cel) in two independent cohorts. Correlative findings were…

…n expanded multi-trial meta-cohort of 586 patients treated with axi-cel. Product characterization was performed with scRNAseq and scATA…

…iling of infusion products from r/r DLBCL patients treated with axicabtagene ciloleucel.Methods Infusion products from eight r/r DLBCL patients with va…

…ior outcome for patients receiving anti-CD19 CAR-T cell therapy axicabtagene ciloleucel (axi-cel) versus historical standard of care. However, about 60…

…rformed in 170 patients with LBCL treated with standard of care axicabtagene ciloleucel. Polygenic risk score instruments for blood cell traits and inf…